Navigation Links
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Date:5/8/2008

combination with other approved cancer drugs. ENMD-2076 is unique-in-class because it not only inhibits Aurora A selectively, it also inhibits a cluster of kinases that are important for tumor growth, particularly growth factor receptors critical to angiogenesis. ENMD-2076 has potent antitumor activity in multiple preclinical models, including both solid tumors and hematological cancers."

James S. Burns, EntreMed President & Chief Executive Officer commented, "Further development of ENMD-2076 is consistent with both our focus on investing behind oncology drug candidates with strong single-agent activity and our continuing interest in kinase inhibitors. In keeping with our 2008 goals of cash preservation and rigorous resource management, we intend to pay the $2 million Phase 1 milestone to Miikana shareholders in shares of EntreMed common stock. Our goals for this program over the next twelve months are to complete the clinical trial in solid tumor patients, initiate a clinical trial in patients with hematological cancers, and secure a pharmaceutical partner to help accelerate the development of ENMD-2076."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at '/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (PRWEB) July 23, 2014 a2z Inc. ... ChirpE Mobile App, AACC Pathfinder, in its 2014 ... AACC’s annual meeting is planned for July 29-31, 2014 ... place to be to connect with global leaders in ... management, and other areas of breaking science in laboratory ...
(Date:7/22/2014)... phylum so full of mean little creatures, the yellow-colored Ormia ... -- at least to crickets. Native to the southeastern U.S. ... sort of parasite. It swoops onto the back of a ... its wicked brood to invade, kill and consume the cricket ... possible without the fly,s ability to find a cricket -- ...
(Date:7/22/2014)... New York (PRWEB) July 22, 2014 ... world. The heat produced by controlled fission chain reaction ... This steam pressure is used to drive a power- ... approximately 19% of the world’s total electricity production. Nuclear ... to several under construction, planned and proposed nuclear reactor ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Two new ... Board of Directors at its annual Shareholders Meeting on ... Information Officer of The PFM Group, and Stephen T. ... Center also announced the election of Michael A. DiPiano, ... Vice Chair and Richard P. Jaffe, Esq., of Duane ...
Breaking Biology Technology:AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3Two New Members Elected to University City Science Center Board of Directors 2Two New Members Elected to University City Science Center Board of Directors 3
... and Advice Shared Through Dynamic WikiAnswers Q&A ... ... In a show of support for National,Breast Cancer Awareness Month, Answers.com,s ... http://wiki.answers.com/Q/FAQ/2375 ), where breast cancer survivors,friends and family have gathered to ...
... NEW YORK, Oct. 22 SPO Medical Inc. ... microprocessor,technologies for use in portable monitoring devices, today announced ... sales milestone has,been achieved within three years of the ... of the 100,000 units sold include the patented technology ...
... Pharmacopeia,(Nasdaq: PCOP ), an innovator in the discovery ... Dr. Leslie J. Browne,President and Chief Executive Officer, will ... Renshaw 9th Annual Healthcare,Conference. The conference will be held ... Hotel in New York City. Dr. Browne,s presentation ...
Cached Biology Technology:Answers.com's WikiAnswers Supervisors Rallying for National Breast Cancer Awareness Month 2Answers.com's WikiAnswers Supervisors Rallying for National Breast Cancer Awareness Month 3SPO Medical Announces Major Sales Milestone 2SPO Medical Announces Major Sales Milestone 3Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 4
(Date:7/23/2014)... especially the young, are highly sensitive to temperature and ... temperatures within a narrow range. Recently published research led ... School of Arts and Sciences, is the first to ... hive in process similar to how humans and other ... , "This study shows how workers effectively dissipate ...
(Date:7/23/2014)... analysis of Antarctic fur seals, alongside decades of ... effect of climate change on a population of ... the findings show that the seals have significantly ... that are associated with climate conditions. Despite a ... fitness is not passing down through generations, leaving ...
(Date:7/23/2014)... samples cultured from cystic fibrosis patients, scientists at the ... Institute have shown that a new CF drug counteracts ... , The finding, published today in the journal ... protein becomes unstable and loses its ability to function ... The research offers several insights into how novel CF ...
Breaking Biology News(10 mins):How honey bees stay cool 2Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4
... Whitehead Institute scientists report that the gene mutated ... syndrome also prevents activation of mTORC1, a critical nutrient-sensing ... is an unexpected finding, as some cancers keep this ... expansion. In the case of Birt-Hogg-Dub syndrome, the mutated ...
... of ZooKeys - no. 346 ... on its day of publication last Friday. This marks ... taxonomic names for animals. The innovative workflow was jointly ... and a U.S. National Science Foundation project to ...
... The Prime Minister of Malaysia today outlined his country,s ... development goals, saying they need to address the relief ... concerns. Prime Minister Najib Razak commended the Millennium ... eight objectives agreed by nations in 2000 for completion ...
Cached Biology News:Gene responsible for hereditary cancer syndrome found to disrupt critical growth-regulating pathway 2Next-generation global e-infrastructure for taxon names registry 2As world sets new development goals, Malaysia calls for poverty relief within green agenda 2As world sets new development goals, Malaysia calls for poverty relief within green agenda 3As world sets new development goals, Malaysia calls for poverty relief within green agenda 4
... Synucleins are small, soluble proteins expressed ... tumors. The family includes three known proteins: ... The alpha and beta synuclein proteins are ... are seen mainly in presynaptic terminals. ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
... Finnpipette BioControl multichannel has ... as the single channel ... fits allseven multichannel and ... cone modules. Both pipettes ...
Biology Products: